Topical Lidocaine on the Cervix and Intra-Cervical Prior to Insertion of Intrauterine Devices

NCT ID: NCT01192490

Last Updated: 2011-06-16

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 210 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-08-31
• Study Completion Date: 2012-12-31

Brief Summary

The hypothesis of this study is that topical cervical and intra-cervical lidocaine will decrease pain associated with the insertion of a Mirena® (levonorgestrel intrauterine device).

1. Primary Aim- Determine if topical lidocaine intra-cervically and on the cervix decreases the pain associated with insertion of a Mirena® (levonorgestrel intrauterine device).

Detailed Description

There have been multiple studies performed to determine a medication that will decrease the pain associated with intrauterine device insertion. These studies have tested the use of misoprostol as well as NSAIDS to determine if these decrease the pain associated with insertion. There has also been one small, poorly performed, study that tested the use of intracervical topical lidocaine prior to IUD insertion. Misoprostol and NSAIDS were found to be non-efficacious in decreasing pain. Topical lidocaine was shown to be effective, however, secondary to this being a poorly performed study, additional studies are needed. This study is to determine if topical lidocaine does indeed decrease the pain associated with insertion of the Mirena® (levonorgestrel intrauterine device).

This is a double blinded experimental study to determine whether or not topical lidocaine gel applied to the cervix and intra-cervically decreases pain associated with insertion of the Mirena® (levonorgestrel intrauterine device). Subjects will be randomized into two groups. One group will receive 2% lidocaine gel on the cervix and intra-cervically. The other group will receive a placebo, which will consist of KY being placed on the cervix and intra-cervically. After the Mirena® (levonorgestrel intrauterine device) is inserted, each subject's pain will be assessed by using a visual analog pain scale, and their response will be recorded on the information form. This pain scale will be assessed at the time of insertion, five minutes after insertion, and ten minutes after insertion. The only other study that researched the use of topical lidocaine prior to insertion of an IUD only recorded a pain scale at the time of insertion. Additional scores will be recorded at five and ten minutes to determine if pain is reduced in those time periods. These time periods have been chosen in order that all of this information can be recorded during a normal office visit. A visual analog pain scale is the scale included which measures pain on a scale of zero to ten with zero being no pain at all and ten being the worst pain of your life. This pain scale will be a scale ranging from zero to ten with faces depicting the amount of pain involved for each score. Since there will be different physicians placing the intrauterine devices, there will be a protocol on how to perform the insertion in an attempt to make all insertions as uniform as possible. A copy of this protocol has been included.

Conditions

Contraception

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: DOUBLE

Study Groups

Lidocaine Arm

This arm will receive intracervical and cervical lidocaine prior to placement of a Mirena.

Group Type: EXPERIMENTAL

Lidocaine

Intervention Type: DRUG

5cc of 2% Lidocaine gel will be placed on the cervix and intra-cervically prior to placement of a Mirena

Lubricant

Subjects in this arm will receive KY gel intracervically and on the cervix prior to placement of a Mirena.

Group Type: PLACEBO_COMPARATOR

Lubricant

Intervention Type: DRUG

KY Gel will be placed on the cervix and intra-cervically prior to placement of the Mirena

Interventions

Lidocaine

5cc of 2% Lidocaine gel will be placed on the cervix and intra-cervically prior to placement of a Mirena

Intervention Type: DRUG

Lubricant

KY Gel will be placed on the cervix and intra-cervically prior to placement of the Mirena

Intervention Type: DRUG

Other Intervention Names

Mirena; KY gel

Eligibility Criteria

Inclusion Criteria

1. Any subject receiving a Mirena® (levonorgestrel intrauterine device) for standard indications.

2. Subjects who received nonsteroidal anti-inflammatory drugs (NSAIDS) will not be excluded.

Exclusion Criteria

1. Subjects do not desire to be involved in the study

2. Subjects who have taken narcotics.

3. If the Mirena® (levonorgestrel intrauterine device) is not able to be successfully placed.

4. If cervical dilation is required, these subjects will be placed in a separate subset and will be reported on separately.

5. Subject has allergy to lidocaine.

• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

University of Tennessee

OTHER

Sponsor Role: lead

Responsible Party

University of Tennessee Chattanooga Department of Obstetrics and Gynecology

Principal Investigators

Kirk Brody, MD

Role: PRINCIPAL_INVESTIGATOR

University of Tennessee Chattanooga Department of Obstetrics and Gynecology

Locations

University of Tennessee Chattanooga Department of Obstetrics and Gynecology

Chattanooga, Tennessee, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Ben Moore, MD

Role: CONTACT

benatmc@hotmail.com

423-778-7515

Brett Bryant, MD

Role: CONTACT

bryant_brett@hotmail.com

423-778-7515

Facility Contacts

Ben Moore, MD

Role: primary

benatmc@hotmail.com

423-778-2580

Brett Bryant, MD

Role: backup

brett_bryant@hotmail.com

423-778-7515

Other Identifiers

00002301

Identifier Type: -

Identifier Source: org_study_id